Federico Pea

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 75

Top Venues

Antibiotics (Basel, Switzerland)

Pharmaceutics

Expert review of anti-infective therapy

Antimicrobial agents and chemotherapy

University of Udine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Udine Jun 1o 2018

Italy

Associate Professor of Pharmacology :: Department of Medicine

Publications

Pier Giorgio Cojutti, Aaron J Heffernan, Thomas Tängdén, Paola Della Siega, Carlo Tascini, Jason Alexander Roberts, Federico Pea
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. Antimicrobial agents and chemotherapy 67 (3) (2023)
Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring. Antibiotics (Basel, Switzerland) 12 (4) (2023)
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study. Pharmaceutics 15 (3) (2023)
Milo Gatti, Federico Pea
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert review of anti-infective therapy 21 (2) (2023)
Milo Gatti, Federico Pea
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert review of anti-infective therapy 21 (2) (2023)
Pier Giorgio Cojutti, Aaron J Heffernan, Thomas Tängdén, Paola Della Siega, Carlo Tascini, Jason Alexander Roberts, Federico Pea
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. Antimicrobial agents and chemotherapy 67 (3) (2023)
Carla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients. Pharmaceutics 15 (2) (2023)
Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration. Antibiotics (Basel, Switzerland) 12 (10) (2023)
Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections. Pharmaceutics 15 (2) (2023)
Altea Gallerani, Milo Gatti, Andrea Bedini, Stefania Casolari, Gabriella Orlando, Cinzia Puzzolante, Erica Franceschini, Marianna Menozzi, Antonella Santoro, Nicole Barp, Sara Volpi, Alessandra Soffritti, Federico Pea, Cristina Mussini, Marianna Meschiari
Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections. Antibiotics (Basel, Switzerland) 12 (11) (2023)
Milo Gatti, Federico Pea
Comment on: pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections. The Journal of antimicrobial chemotherapy (2023)
Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections. Pharmaceutics 15 (2) (2023)
Milo Gatti, Giacomo Fornaro, Zeno Pasquini, Andrea Zanoni, Michele Bartoletti, Pierluigi Viale, Federico Pea
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis. Antibiotics (Basel, Switzerland) 12 (4) (2023)
Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring. Antibiotics (Basel, Switzerland) 12 (4) (2023)
Carla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients. Pharmaceutics 15 (2) (2023)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence. Microorganisms 11 (2) (2023)
Milo Gatti, Federico Pea
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert review of anti-infective therapy (2023)
Milo Gatti, Pierluigi Viale, Federico Pea
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run. The Journal of antimicrobial chemotherapy (2023)
Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, Paolo Gaibani, Maddalena Giannella, Pierluigi Viale, Federico Pea
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? Antimicrobial agents and chemotherapy (2023)
Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections. Pharmaceutics 15 (2) (2023)
Milo Gatti, Giacomo Fornaro, Zeno Pasquini, Andrea Zanoni, Michele Bartoletti, Pierluigi Viale, Federico Pea
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis. Antibiotics (Basel, Switzerland) 12 (4) (2023)
Milo Gatti, Federico Pea
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan. Expert review of clinical pharmacology (2023)
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study. Pharmaceutics 15 (3) (2023)
Pier Giorgio Cojutti, Aaron J Heffernan, Thomas Tängdén, Paola Della Siega, Carlo Tascini, Jason Alexander Roberts, Federico Pea
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. Antimicrobial agents and chemotherapy 67 (3) (2023)
Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections. Pharmaceutics 15 (2) (2023)
Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring. Antibiotics (Basel, Switzerland) 12 (2) (2023)
Alessandra Oliva, Francesco Giuseppe De Rosa, Malgorzata Mikulska, Federico Pea, Maurizio Sanguinetti, Carlo Tascini, Mario Venditti
Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin. Expert review of anti-infective therapy (2023)
Carla Troisi, Pier Giorgio Cojutti, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients. Pharmaceutics 15 (2) (2023)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence. Microorganisms 11 (2) (2023)
Pier Giorgio Cojutti, Aaron J Heffernan, Thomas Tängdén, Paola Della Siega, Carlo Tascini, Jason Alexander Roberts, Federico Pea
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. Antimicrobial agents and chemotherapy (2023)
Milo Gatti, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections. Antibiotics (Basel, Switzerland) 12 (11) (2023)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence. Microorganisms 11 (2) (2023)
Rossella Barone, Matteo Conti, Pier Giorgio Cojutti, Milo Gatti, Pierluigi Viale, Federico Pea
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring. Antibiotics (Basel, Switzerland) 12 (2) (2023)
Milo Gatti, Federico Pea
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert review of anti-infective therapy 21 (2) (2023)
Pasquale Maria Berrino, Milo Gatti, Matteo Rinaldi, Eugenio Brunocilla, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections. Antibiotics (Basel, Switzerland) 12 (9) (2023)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence. Microorganisms 11 (2) (2023)
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study. Pharmaceutics 15 (3) (2023)
Milo Gatti, Federico Pea
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert review of anti-infective therapy (2023)
Pier Giorgio Cojutti, Aaron J Heffernan, Thomas Tängdén, Paola Della Siega, Carlo Tascini, Jason Alexander Roberts, Federico Pea
Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. Antimicrobial agents and chemotherapy 67 (3) (2023)
Milo Gatti, Federico Pea
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. Expert review of anti-infective therapy 21 (2) (2023)
Pier Giorgio Cojutti, Giacomo Fornaro, Milo Gatti, Matteo Rinaldi, Paolo Gaibani, Maddalena Giannella, Federico Pea, Pierluigi Viale
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring. Infectious disease reports 14 (1) (2022)
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Pier Giorgio Cojutti, Sara Tedeschi, Milo Gatti, Eleonora Zamparini, Marianna Meschiari, Paola Della Siega, Mazzitelli Maria, Laura Soavi, Raffaella Binazzi, Elke Maria Erne, Marco Rizzi, Anna Maria Cattelan, Carlo Tascini, Cristina Mussini, Pierluigi Viale, Federico Pea
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring. Antibiotics (Basel, Switzerland) 11 (8) (2022)
Milo Gatti, Sara Tedeschi, Filippo Trapani, Stefania Ramirez, Rita Mancini, Maddalena Giannella, Pierluigi Viale, Federico Pea
A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis. Antibiotics (Basel, Switzerland) 11 (8) (2022)
Mazzitelli Maria, Milo Gatti, Vincenzo Scaglione, Daniele Mengato, Marco Trevenzoli, Andrea Sattin, Federico Pea, Anna Maria Cattelan
Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus : A Retrospective Single-Centre Experience. Antibiotics (Basel, Switzerland) 11 (10) (2022)
Milo Gatti, Federico Pea
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions. Clinical pharmacokinetics 61 (11) (2022)
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Maria Sanz-Codina, Milo Gatti, Carla Troisi, Giacomo Fornaro, Zeno Pasquini, Filippo Trapani, Andrea Zanoni, Fabio Caramelli, Pierluigi Viale, Federico Pea
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem. Pharmaceutics 14 (8) (2022)
Milo Gatti, Giulio Virgili, Pier Giorgio Cojutti, Paolo Gaibani, Matteo Conti, Carmelo Sturiale, Federico Pea, Pierluigi Viale
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two Cases. Microorganisms 10 (1) (2022)
Milo Gatti, Giacomo Fornaro, Pierluigi Viale, Federico Pea, Maddalena Giannella
Clinical efficacy of renal dosing adjustments of ceftazidime-avibactam in patients affected by carbapenem-resistant Gram-negative infections: A systematic review and meta-analysis of observational studies. British journal of clinical pharmacology (2022)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics (Basel, Switzerland) 11 (1) (2021)
Pier Giorgio Cojutti, Alessia Carnelutti, Davide Lazzarotto, Emanuela Sozio, Anna Candoni, Renato Fanin, Carlo Tascini, Federico Pea
Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles? Pharmaceutics 13 (12) (2021)
Milo Gatti, Massimo Andreoni, Federico Pea, Pierluigi Viale
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Drug design, development and therapy 15 (2021)
Milo Gatti, Pier Giorgio Cojutti, Renato Pascale, Tommaso Tonetti, Cristiana Laici, Alessio Dell'Olio, Antonio Siniscalchi, Maddalena Giannella, Pierluigi Viale, Federico Pea
Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. Antibiotics (Basel, Switzerland) 10 (11) (2021)
Massimo Andreoni, Matteo Bassetti, Salvatore Corrao, Francesco Giuseppe De Rosa, Vincenzo Esposito, Marco Falcone, Paolo Antonio Grossi, Federico Pea, Nicola Petrosillo, Carlo Tascini, Mario Venditti, Pierluigi Viale
The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert review of anti-infective therapy 19 (9) (2021)
Milo Gatti, Federico Pea
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics. Clinical pharmacokinetics 60 (10) (2021)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients. Infection and drug resistance 14 (2021)
Matteo Rinaldi, Pier Giorgio Cojutti, Eleonora Zamparini, Sara Tedeschi, Nicolò Rossi, Matteo Conti, Maddalena Giannella, Federico Pea, Pierluigi Viale
Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction. Antimicrobial agents and chemotherapy (2021)
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea, Pierluigi Viale
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients. Expert review of anti-infective therapy (2021)
Giusy Tiseo, Fabio Arena, Silvio Borrè, Floriana Campanile, Marco Falcone, Cristina Mussini, Federico Pea, Gabriele Sganga, Stefania Stefani, Mario Venditti
Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. Expert review of anti-infective therapy 19 (11) (2021)
Milo Gatti, Federico Pea
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. Expert review of clinical pharmacology 14 (5) (2021)
Milo Gatti, Fabrizio de Ponti, Federico Pea
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies. CNS drugs 35 (4) (2021)
Pier Giorgio Cojutti, Matteo Rinaldi, Eleonora Zamparini, Nicolò Rossi, Sara Tedeschi, Matteo Conti, Federico Pea, Pierluigi Viale
Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?" Antimicrobial agents and chemotherapy (2021)
Milo Gatti, Federico Pea
Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections? Clinical pharmacokinetics 60 (4) (2021)
Pier Giorgio Cojutti, Matteo Rinaldi, Eleonora Zamparini, Nicolò Rossi, Sara Tedeschi, Matteo Conti, Federico Pea, Pierluigi Viale
Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrobial agents and chemotherapy (2021)
Pier Giorgio Cojutti, Angela Londero, Paola Della Siega, Filippo Givone, Martina Fabris, Jessica Biasizzo, Carlo Tascini, Federico Pea
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clinical pharmacokinetics 59 (10) (2020)
Alex Soriano, Gian Maria Rossolini, Federico Pea
The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Expert review of anti-infective therapy 18 (5) (2020)
Federico Pea
From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis. Mycoses 63 (8) (2020)
Pier Giorgio Cojutti, Anna Candoni, Davide Lazzarotto, Carla Filì, Maria Zannier, Renato Fanin, Federico Pea
Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa. Pharmaceutics 12 (9) (2020)
Piergiorgio Cojutti, Manjunath P Pai, Federico Pea
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clinical pharmacokinetics 57 (8) (2019)
Pier Giorgio Cojutti, Cristina Barbarino, Amato De Monte, William Hope, Federico Pea
Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. European journal of clinical pharmacology 74 (8) (2018)
Pier Giorgio Cojutti, Anna Candoni, Davide Lazzarotto, Nicholas Rabassi, Renato Fanin, William Hope, Federico Pea
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. British journal of clinical pharmacology 84 (11) (2018)
Pier Giorgio Cojutti, Maria Merelli, Paola De Stefanis, Cleo Fregonese, Francesca Lucchese, Matteo Bassetti, Federico Pea
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. European journal of clinical pharmacology 74 (12) (2018)
Pier Giorgio Cojutti, Maria Merelli, Lorenzo Allegri, Giuseppe Damante, Matteo Bassetti, Federico Pea
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. British journal of clinical pharmacology 85 (1) (2018)

Federico Pea.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Federico Pea